Previous scientific research has found multiple genes that affect the risk for developing heart disease or complications during the treatment of heart disease. Less is currently known about how patients with heart disease may differ on the basis of other ailments they may have and how these other ailments may affect their treatment and prognosis. For this reason, researchers at the Mid America Heart Institute are conducting this research to find out how genes affect heart disease and recovery following angioplasty. The study will include patients with diabetes in order to determine if their genes are different from patients without diabetes.

A total of 1,607 patients were enrolled. There were 2 groups of patients selected for this study. The first group of patients included into the study will be those that are scheduled to have a diagnostic angiogram only. The second group of patients were those that had along with the angiogram a percutaneous transluminal coronary angioplasty, PTCA and or the use of a device called a coronary "stent", designed to help prop open the artery and to help avoid collapse. Samples for both groups will be stored for 30 years. After this time, all samples will be destroyed. Ultimately, we are hopeful that we will identify genes that will identify groups of patients at risk for heart disease.

A single-center prospective registry which enrolled 1,607 patients. Following informed consent, patients underwent coronary angiography and/or percutaneous coronary intervention. This project was funded by an institution grant, philanthropy, industry, and a grant from the American Diabetes Association. The long-term goal is to better understand the biological underpinnings associated with diabetic atherosclerosis and vascular risk attributable to diabetes. All patients also provided informed consent for blood banking. Blood samples were collected at baseline (fasting) and in patients undergoing PCI (random) at 2,8 and 16 hours following arterial injury. These samples were separated in aliquots of 12 x1000µL, 10x500µL EDTA plasma, 2x1,000 µL and 20x200 µL of buffy coat (baseline only) and 2x1,000 µL of RBCs (baseline only). This protocol was designed to perform multiple biomarker studies as it avoids multiple freeze thaw cycles. A plaque imaging sub-study using the IVUS-VH software platform to characterize plaque tissue enrolled 209 patients.

Inclusion Criteria:

• Male or female gender
• Diabetes mellitus or no diabetes mellitus
• Candidate for percutaneous coronary intervention
• Informed consent

Regional population attending a single-center specialty care clinic